Paediatric extracranial germ-cell tumours

Furqan Shaikh, Matthew J. Murray, James F. Amatruda, Nicholas Coleman, James C. Nicholson, Juliet P. Hale, Farzana Pashankar, Sara J. Stoneham, Jenny N. Poynter, Thomas A. Olson, Deborah F. Billmire, Daniel Stark, Carlos Rodriguez-Galindo, A. Lindsay Frazier

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Management of paediatric extracranial germ-cell tumours carries a unique set of challenges. Germ-cell tumours are a heterogeneous group of neoplasms that present across a wide age range and vary in site, histology, and clinical behaviour. Patients with germ-cell tumours are managed by a diverse array of specialists. Thus, staging, risk stratification, and treatment approaches for germ-cell tumours have evolved disparately along several trajectories. Paediatric germ-cell tumours differ from the adolescent and adult disease in many ways, leading to complexities in applying age-appropriate, evidence-based care. Suboptimal outcomes remain for several groups of patients, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis, or platinum-resistant disease. Survivors have significant long-term toxicities. The challenge moving forward will be to translate new insights from molecular studies and collaborative clinical data into improved patient outcomes. Future trials will be characterised by improved risk-stratification systems, biomarkers for response and toxic effects, rational reduction of therapy for low-risk patients and novel approaches for poor-risk patients, and improved international collaboration across paediatric and adult cooperative research groups.

Original languageEnglish (US)
Pages (from-to)e149-e162
JournalThe Lancet Oncology
Volume17
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Germ Cell and Embryonal Neoplasms
Pediatrics
Poisons
Tumor Biomarkers
Platinum
Survivors
Neoplasms
Histology
Biomarkers
Therapeutics
Research

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology

Cite this

Shaikh, F., Murray, M. J., Amatruda, J. F., Coleman, N., Nicholson, J. C., Hale, J. P., ... Frazier, A. L. (2016). Paediatric extracranial germ-cell tumours. The Lancet Oncology, 17(4), e149-e162. https://doi.org/10.1016/S1470-2045(15)00545-8

Paediatric extracranial germ-cell tumours. / Shaikh, Furqan; Murray, Matthew J.; Amatruda, James F.; Coleman, Nicholas; Nicholson, James C.; Hale, Juliet P.; Pashankar, Farzana; Stoneham, Sara J.; Poynter, Jenny N.; Olson, Thomas A.; Billmire, Deborah F.; Stark, Daniel; Rodriguez-Galindo, Carlos; Frazier, A. Lindsay.

In: The Lancet Oncology, Vol. 17, No. 4, 01.04.2016, p. e149-e162.

Research output: Contribution to journalReview article

Shaikh, F, Murray, MJ, Amatruda, JF, Coleman, N, Nicholson, JC, Hale, JP, Pashankar, F, Stoneham, SJ, Poynter, JN, Olson, TA, Billmire, DF, Stark, D, Rodriguez-Galindo, C & Frazier, AL 2016, 'Paediatric extracranial germ-cell tumours', The Lancet Oncology, vol. 17, no. 4, pp. e149-e162. https://doi.org/10.1016/S1470-2045(15)00545-8
Shaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JP et al. Paediatric extracranial germ-cell tumours. The Lancet Oncology. 2016 Apr 1;17(4):e149-e162. https://doi.org/10.1016/S1470-2045(15)00545-8
Shaikh, Furqan ; Murray, Matthew J. ; Amatruda, James F. ; Coleman, Nicholas ; Nicholson, James C. ; Hale, Juliet P. ; Pashankar, Farzana ; Stoneham, Sara J. ; Poynter, Jenny N. ; Olson, Thomas A. ; Billmire, Deborah F. ; Stark, Daniel ; Rodriguez-Galindo, Carlos ; Frazier, A. Lindsay. / Paediatric extracranial germ-cell tumours. In: The Lancet Oncology. 2016 ; Vol. 17, No. 4. pp. e149-e162.
@article{97b2223d4fa64446b5b56a31f04d0a6c,
title = "Paediatric extracranial germ-cell tumours",
abstract = "Management of paediatric extracranial germ-cell tumours carries a unique set of challenges. Germ-cell tumours are a heterogeneous group of neoplasms that present across a wide age range and vary in site, histology, and clinical behaviour. Patients with germ-cell tumours are managed by a diverse array of specialists. Thus, staging, risk stratification, and treatment approaches for germ-cell tumours have evolved disparately along several trajectories. Paediatric germ-cell tumours differ from the adolescent and adult disease in many ways, leading to complexities in applying age-appropriate, evidence-based care. Suboptimal outcomes remain for several groups of patients, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis, or platinum-resistant disease. Survivors have significant long-term toxicities. The challenge moving forward will be to translate new insights from molecular studies and collaborative clinical data into improved patient outcomes. Future trials will be characterised by improved risk-stratification systems, biomarkers for response and toxic effects, rational reduction of therapy for low-risk patients and novel approaches for poor-risk patients, and improved international collaboration across paediatric and adult cooperative research groups.",
author = "Furqan Shaikh and Murray, {Matthew J.} and Amatruda, {James F.} and Nicholas Coleman and Nicholson, {James C.} and Hale, {Juliet P.} and Farzana Pashankar and Stoneham, {Sara J.} and Poynter, {Jenny N.} and Olson, {Thomas A.} and Billmire, {Deborah F.} and Daniel Stark and Carlos Rodriguez-Galindo and Frazier, {A. Lindsay}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/S1470-2045(15)00545-8",
language = "English (US)",
volume = "17",
pages = "e149--e162",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "4",

}

TY - JOUR

T1 - Paediatric extracranial germ-cell tumours

AU - Shaikh, Furqan

AU - Murray, Matthew J.

AU - Amatruda, James F.

AU - Coleman, Nicholas

AU - Nicholson, James C.

AU - Hale, Juliet P.

AU - Pashankar, Farzana

AU - Stoneham, Sara J.

AU - Poynter, Jenny N.

AU - Olson, Thomas A.

AU - Billmire, Deborah F.

AU - Stark, Daniel

AU - Rodriguez-Galindo, Carlos

AU - Frazier, A. Lindsay

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Management of paediatric extracranial germ-cell tumours carries a unique set of challenges. Germ-cell tumours are a heterogeneous group of neoplasms that present across a wide age range and vary in site, histology, and clinical behaviour. Patients with germ-cell tumours are managed by a diverse array of specialists. Thus, staging, risk stratification, and treatment approaches for germ-cell tumours have evolved disparately along several trajectories. Paediatric germ-cell tumours differ from the adolescent and adult disease in many ways, leading to complexities in applying age-appropriate, evidence-based care. Suboptimal outcomes remain for several groups of patients, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis, or platinum-resistant disease. Survivors have significant long-term toxicities. The challenge moving forward will be to translate new insights from molecular studies and collaborative clinical data into improved patient outcomes. Future trials will be characterised by improved risk-stratification systems, biomarkers for response and toxic effects, rational reduction of therapy for low-risk patients and novel approaches for poor-risk patients, and improved international collaboration across paediatric and adult cooperative research groups.

AB - Management of paediatric extracranial germ-cell tumours carries a unique set of challenges. Germ-cell tumours are a heterogeneous group of neoplasms that present across a wide age range and vary in site, histology, and clinical behaviour. Patients with germ-cell tumours are managed by a diverse array of specialists. Thus, staging, risk stratification, and treatment approaches for germ-cell tumours have evolved disparately along several trajectories. Paediatric germ-cell tumours differ from the adolescent and adult disease in many ways, leading to complexities in applying age-appropriate, evidence-based care. Suboptimal outcomes remain for several groups of patients, including adolescents, and patients with extragonadal tumours, high tumour markers at diagnosis, or platinum-resistant disease. Survivors have significant long-term toxicities. The challenge moving forward will be to translate new insights from molecular studies and collaborative clinical data into improved patient outcomes. Future trials will be characterised by improved risk-stratification systems, biomarkers for response and toxic effects, rational reduction of therapy for low-risk patients and novel approaches for poor-risk patients, and improved international collaboration across paediatric and adult cooperative research groups.

UR - http://www.scopus.com/inward/record.url?scp=84977556590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977556590&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)00545-8

DO - 10.1016/S1470-2045(15)00545-8

M3 - Review article

C2 - 27300675

AN - SCOPUS:84977556590

VL - 17

SP - e149-e162

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -